Decarboxyprothrombin : Diagnostic value in hepatocellular carcinoma;La decarboxyprothrombine : interet dans le diagnostic du carcinome hepatocellulaire

Annales de Biologie Clinique

Volumn 56, Issue 2, 1998, Pages 175-181

  Bon, C ^a   Brillard, B ^a   Gelineau, M C ^a   Mailliavin, A ^a   Trepo C ^a   Pichot, J ^a  

^a HÔTEL DIEU   (France)

Author keywords

Alpha foeto protein; Decarboxyprothrombin; Hepatocarcinoma; Tumor markers

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; BIOLOGICAL MARKER; DIAGNOSTIC AGENT; DRUG DERIVATIVE; PROTEIN PRECURSOR; PROTHROMBIN; TUMOR MARKER;

ADULT; AGED; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME IMMUNOASSAY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; BLOOD; DIFFERENTIAL DIAGNOSIS; LIVER TUMOR; MIDDLE AGED; SENSITIVITY AND SPECIFICITY;

HEPATITIS C VIRUS;

ADULT; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROTEIN PRECURSORS; PROTHROMBIN; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0032014140     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Giraud C. Les marqueurs tumoraux dans les cancers du foie. Rev Fr Lab 1993; 257 : 61-8.
2. Colombo M. Hepatocellular carcinoma in cirrhotics. Semin Liver Dis 1993 ; 13 : 374-83.
3. Erlinger S. Les carcinomes hépatocellulaires. Impact Médecin. Les dossiers du praticien ; 1992 ; 136 : 1-22.
4. Ikeda K, Saitoh S, Koida I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis : a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatotogy 1993; 18 : 47-53.
5. Ganne-Carrié N, Chastang C, Chapel F, et al. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in western patients with cirrhosis. Hepatology 1996; 23 : 1112-8.
6. Liebman HA, Furie BC, Tong MJ, et al. Des-γ-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984 ; 310 : 1427-31.
7. Soulier JP, Lefrère JJ, Gozin D. Le dosage de la décarboxy-prothrombine. Son intérêt dans le diagnostic des carcinomes hépatocellulaires. Ann Med Interne 1988; 13 : 7-11.
8. Fujiyama S, Morishita T, Hashiguchi O, Sato T. Plasma abnormal prothrombin (des-γ-carboxy-prothrombin) as a marker of hepato-cellular carcinoma. Cancer 1988 ; 61 : 1621-8.
9. Fujiyama S, Izuno K, Gohshi K, Shibata J, Sato T. Clinical usefulness of des-γ-carboxy-prothrombin assay in early diagnosis of hepatocellular carcinoma. Dig Dis Sci 1991 ; 36 : 1787-92.
10. Takikawa Y, Suzuki K, Yamazaki K, et al. Plasma abnormal prothrombin (Pivka-II) : a new and reliable marker for the detection of hepatocellular carcinoma. J Gastroenterol Hepatol 1992 ; 7 : 1-6.
11. Tanabe Y, Ohnishi K, Nomura F, Iida S. Plasma abnormal prothrombin levels in patients with small hepatocellular carcinoma. Am J Gastroenterol 1988 ; 83 : 1386-9.
12. Beaugrand M, Van Den Abeele S, Mai F, et al. Le dosage de la dégammacarboxy-prothrombine (DCP) est-il utile au diagnostic et au dépistage du carcinome hépatocellulaire chez le cirrhotique ? Résultats d'une étude prospective chez 152 malades. Gastroenterol Clin Biol 1988 ; 12 : 18.
13. Widdershoven J, Van Munster P, De Abreu R, et al. Four methods compared for measuring des-carboxy-prothrombin (Pivka-II). Clin Chem 1987; 33 : 2074-8.
14. Soulier JP, Gozin D, Lefrère JJ. Nouvelle méthode de dosage fonctionnel de la dégamma-carboxyprothrombine à l'aide de staphylocoagulase. Presse Méd 1985 ; 14 : 2049-52.
15. Francis JL. A rapid and simple micromethod for the specific determination of descarboxylated prothrombin (Pivka II). Medical Laboratory Sciences 1988 ; 45 : 69-73.
16. Amiral J, Grosley M, Plassart V, Mimilla F, Chambrette B. Development of a monoclonal immunoassay for the direct measurement of decarboxy prothrombin on plasma. XIIIth congress of ISTH. Amsterdam. The Netherlands, June 30-July 6. Thromb Haemostasis 1991 ; 65 : 648.
17. Furukawa M, Nakanishi T, Okuda H, Ishida S, Obata M. Changes of plasma des-γ-carboxyprothrombin levels in patients with hepatocellular carcinoma in response to vitamine K. Cancer 1992 ; 69 : 31-8.
18. Huisse MG, Leclercq M, Belghiti J, et al. Mechanism of the abnormal vitamin K-dependent γ-carboxylation process in human hepatocellular carcinomas. Cancer 1994 ; 74 : 1533-41.
19. Yamagata H, Nakanishi T, Furukawa M, Okuda H, Obata H. Levels of vitamin K, immunoreactive prothrombin, des-γ-carboxy prothrombin and γ-glutamyl carboxylase activity in hepatocellular carcinoma tissue. J Gaslroenterot Hepatol 1995 ; 10 : 8-13.
20. Soulier JP, Gozin D, Lefrère JJ. A new method to assay des-γ-carboxyprothrombin. Gastroenterology 1986 ; 91 : 1258-62.
21. Inoue S, Nakao A, Harada A, Nonami T, Takagi H. Clinical significance of abnormal prothrombin (DCP) in relation to postoperative survival and prognosis in patients with hepatocellular carcinoma. Am J Gastroenterol 1994 ; 89 : 2222-6.
22. Kasahara A, Hayashi N, Fusamoto H, et al. Clinical evaluation of plasma des-γ-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes. Dig Dis Sci 1993 ; 38 : 2170-6.
23. Suehiro T, Matsumata T, Itasaka H, Tabetomi A, Yamamoto K, Sugimachi K. Des-gamma-carboxy prothrobin and proliferative activity of hepatocellular carcinoma. Surgery 1995 ; 117 : 682-91.
24. Nakao A, Taniguchi K, Inoue S, et al. Usefulness of simultaneous determination of α-Fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma. Sem Surg Oncol 1996 ; 12 : 160-3.
25. Izuno K, Fujiyama S, Yamasaki K, Sato M, Sato T. Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-y-carboxy prothrombin and α-fetoprotein : a prospective study. Hepatol Gastroenterol 1995 ; 42 : 387-93.
26. Aoyagi Y, Oguro M, Yanagi M, et al. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma. Cancer 1996 ; 77 : 1781-6.
27. Soulier JP, Gozin D, Lefrère JJ. Assay of des-gamma-carboxyprothrombin using staphylo-coagulase. Application to the diagnosis of cellular hepatocarcinoma. Haematologica 1986 ; 19 : 3-12.
28. Pateron D, Ganne N, Trinchet JC, et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994; 20: 65-71.
29. Tsai SL, Huang GT, Yang PM, Shen JC, Sung JL, Chen DS. Plasma des-γ-carboxy-prothrombin in the early stage of hepatocellular carcinoma. Hepatology 1990 ; 11 : 481-8.
30. Saitoh S, Ikeda K, Koida I, Isubota A, Arase Y, Chayama K, Kumada H. Serum des-gamma-carboxyprothrombin concentration determined by the avidin-biotin complex method in small hepatocellular carcinomas. Cancer 1994 ; 74 : 2918-23.
31. Nomura F, Ishijima M, Horikoshi A, Nakai T, Ohnishi K. Determination of serum des-gamma-carboxy prothrombin levels in patients with small-sized hepatocellular carcinoma : comparison of the conventional enzyme immunoassay and two modified methods. Am J Gastroenterol 1996; 91 : 1380-3.
32. Sakon M, Monden M, Gotoh M, et al. Relationship between pathologic prognostic factors and abnormal levels of des-γ-carboxy prothrombin and α-fetoprotein in hepatocellular carcinoma. Am J Surgery 1992 ; 163 : 251-6.